https://imaginab.com/clinical-trials/zr-89-crefmirlimab-berdoxam-and-immuno-positron-emission-tomography-for-the-imaging-of-patients-with-resectable-brain-tumors2025-03-05T11:16:09-08:00weekly0.5https://imaginab.com/clinical-trials/cd8-pet-imaging-in-metastatic-solid-tumours2025-03-05T11:44:56-08:00weekly0.5https://imaginab.com/clinical-trials/b-cell-activation-in-sj%C3%B6grens-syndrome-cutaneous-lupus-erythematodus-and-systemic-sclerosis-tissues-analysis-22023-04-13T12:01:59-07:00weekly0.5https://imaginab.com/clinical-trials/a-phase-1-study-of-abc008-in-ascending-single-ascending-dose-multiple-ascending-dose-study-in-patients-with-ibm2025-03-05T11:20:28-08:00weekly0.5https://imaginab.com/clinical-trials/asp8374-cemiplimab-in-recurrent-glioma-22024-10-28T09:37:03-07:00weekly0.5https://imaginab.com/clinical-trials/study-to-evaluate-cd8-pet-imaging-as-a-marker-of-immune-response-to-stereotactic-body-radiation-therapy-elixr2023-04-13T10:28:35-07:00weekly0.5https://imaginab.com/clinical-trials/cd8-minibody-repeatability-study-pretzcel2025-03-05T11:22:46-08:00weekly0.5https://imaginab.com/clinical-trials/a-phase-1-2-study-in-patients-with-hpv16-recurrent-metastatic-head-and-neck-squamous-cell-carcinoma-and-other-cancers2025-03-05T11:23:05-08:00weekly0.5https://imaginab.com/clinical-trials/cd8-t-cell-imaging-during-pre-surgery-immunotherapy-in-people-with-melanoma2025-03-05T11:23:23-08:00weekly0.5https://imaginab.com/clinical-trials/a-first-in-human-study-to-evaluate-the-safety-and-tolerability-of-azd8853-in-participants-with-selected-advanced-metastatic-solid-tumours2025-05-01T05:50:22-07:00weekly0.5https://imaginab.com/clinical-trials/cd8-pet-companion-trial2023-04-13T10:19:33-07:00weekly0.5https://imaginab.com/clinical-trials/study-of-89zr-df-crefmirlimab-pet-ct-in-subjects-with-advanced-or-metastatic-malignancies-ipredict2025-03-05T11:30:33-08:00weekly0.5https://imaginab.com/clinical-trials/imaging-tumor-infiltrating-cd8-t-cells-in-non-small-cell-lung-cancer-upon-neo-adjuvant-treatment-with-durvalumab-medi47362025-03-05T11:36:23-08:00weekly0.5https://imaginab.com/clinical-trials/surgical-nivolumab-and-ipilimumab-for-recurrent-gbm2024-10-28T09:33:41-07:00weekly0.5https://imaginab.com/clinical-trials/a-trial-of-radiotherapy-and-durvalumab-in-dlbcl-and-fl-radd2024-10-28T09:43:36-07:00weekly0.5https://imaginab.com/clinical-trials/an-open-label-multi-center-phase-ib-imaging-sub-study-of-glofitamab-plus-asingle-pre-treatment-dose-of-obinutuzumab-using-89zr-df-iab22m2c-as-cd8-tracer-in-adult-patients-with-relapsed-refractory-b-cell-non-hodgkins-lymphoma2024-10-28T09:49:03-07:00weekly0.5https://imaginab.com/clinical-trials/an-open-label-phase-lb-study-of-glofitamab-and-atezolizumab-or-polatuzumab-vedotin-in-adult-patients-with-relapsed-refractory-b-cell-non-hodgkins-lymphoma2024-10-28T09:48:28-07:00weekly0.5https://imaginab.com/clinical-trials/cd8-t-cell-pet-ct-imaging-in-covid-19-patients-tangelo2024-10-28T09:49:26-07:00weekly0.5https://imaginab.com/clinical-trials/%E2%81%B8%E2%81%B9zr-df-iab22m2c-pet-ct-in-patients-with-selected-solid-malignancies-or-hodgkins-lymphoma2024-10-28T09:49:37-07:00weekly0.5https://imaginab.com/clinical-trials/nct038021232025-03-05T11:43:43-08:00weekly0.5